15 PhD positions in the EU Horizon 2020 Marie-Skłodowska-Curie Project: MSCA-ITN-ETN SINERGIA (# of pos: 15)

Updated: 9 months ago
Deadline: 15 Dec 2019

The Marie Skłodowska-Curie Actions Innovative Training Network (H2020-MSCA-ITN-2019-860715) “Advanced technologieS for drug dIscovery and precisioN mEdicine: in vitRo modellinG human physiology and diseAse” (SINERGIA) invites applications for 15 early-stage researcher (ESR) positions, available with a starting date in the period Feb 1st – May 1st 2020 for a period of three years. The network comprises 10 beneficiaries and 4 partner organisations from both the academic and industrial sectors from 6 countries (Italy, Switzerland, The Netherlands, Czech Republic, Germany and United Kingdom). 

The SINERGIA project provides research and training opportunities for early-stage researchers in the field the emerging technologies in drug development and precision medicine. Specifically, SINERGIA aims at improving the dialogue among the main stakeholders in the drug discovery field, and at developing advanced models of human physiology and diseases, to be ultimately introduced in the preclinical stages of the drug discovery pipeline.

SINERGIA’s research programme addresses three investigational areas of the drug development process – namely drug benefit, drug safety and precision medicine – with the aim of bringing advanced models built on innovative Technologies from bench to the pharmaceutical market. SINERGIA research objectives are: i) drug benefit, ii) drug safety, and iii) precision medicine. SINERGIA’s approach will be:

  • Multi-sectoral, encompassing academia, biotechs and Contact Research Organizations, and also accounting for the support of clinicians from hospitals enrolled as beneficiary or partner organizations
  • Multi-technological, involving the exploitation of different and complementary cutting-edge technologies, i.e. microfluidics, bioreactors, 3D-printing, induced pluripotent stem cells (iPSCs) that will be synergistically used to generate relevant in vitro models of human physiology and diseases
  • Multi-disciplinary, in that the researchers will be involved in individual projects (each leading to PhD degree), spanning from technology development to disease modelling. SINERGIA will establish new in vitro models enabling for drug discovery by taking advantage of cutting-edge technologies that are currently emerging as extremely promising and innovative, either alone ot through their possible combinations.

Training will be achieved either through research or by education. Research training includes Secondments at partner premises, Training by education includes transferable skills training and comprises attendance to both local training activities and network-wide training activities. In addition, ESRs will attend 3 SINERGIA Summer Schools. The ESRs will also have the opportunity to enrol for a PhD.

For further details and to submit your application, please visit www.sinergia2020.polimi.it .

We are looking for highly motivated researchers with an excellent academic background in Bioengineering, Chemistry, Material Science, Biology and Physics.

Applicants must at the time of recruitment:

1) Have a BSc and a MSc or equivalent in Biomedical Engineering, Biotechnology, Physics, Biology, Medicine or a related discipline

2) Be in the first four years (full-time equivalent) of their research careers

3) Have not been awarded a doctoral degree

4) Have not resided in the country of the host beneficiary for more than 12 months in the last 3 years

Principal SINERGIA partners and hosts for ESRs

  • Politecnico di Milano (POLIMI), Milano, Italy
  • Universitat Basel (UNIBAS/USB), Basel, Switzerland
  • Universiteit Maastricht (UMaastricht), Maastricht, The Netherland
  • Fakultni Nemocnice U Sv. Anny V Brne (ICRC Brno), Brno, Czech Republic
  • Universitaetsklinikum Aachen (UKA), Aachen, Germany
  • Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
  • Accelera Srl (ACCELERA), Nerviano, Italy
  • Lifetec Group BV (LIFETEC), Eindhoven, The Netherland
  • BiomimX Srl (BIOMIMX), Milano, Italy
  • MTTLAB SRL (MTTLAB), Udine, Italy
  • Titles of the projects:

  • Developing a miniaturized ex vivo culture system for drug testing on patient-specific tumour specimens. Host: UNIBAS/USB (CH)
  • Generation of a 3D in vitro model to study cardiac fibroblast contribution to myocardial fibrosis. Host: ICRC Brno (CZ)
  • Kidney fibrosis in vitro model. Host: UMaastricht (NL)
  • An in vitro model of skeletal muscle tissue to test anti-fibrotic therapies. Host: EOC (CH)
  • Multi-compartment microfluidic model to improve gut microbiome-mediated immunotherapy efficiency. Host: POLIMI (IT)
  • Bioprinting of kidney rudiment for drug safety screening. Host: UMaastricht (NL)
  • uHeart: an in vitro human miniaturized model for the detection of drug-induced functional cardiotoxicity. Host: BIOMIMX (IT)
  • Set-up and preliminary validation of a modular high-throughput microfluidic system for assessing drug toxicity and metabolism in the hepatobiliary environment. Host: ACCELERA (IT)
  • Validation of in vitro 3D liver model for efficacy and/or toxicology studies. Host: MTTLAB (IT)
  • Development of an ex-vivo liver model to study drug treatment. Host: LIFETEC (NL)
  • Generation of a patient-specific in vitro model of cardiac fibrosis for personalized anti-fibrotic drug screening. Host: ICRC Brno (CZ)
  • Engineering a perfusion-based bioreactor system to study metastatic breast cancer interactions with bone microenvironments. Host: UNIBAS/USB (CH)
  • Microfluidic bone chip to personalize the therapeutic regimen of bone metastatic tumours. Host: EOC (CH)
  • Validation of in vitro approaches for precision based medicine. Host: UKA (DE)
  • Development of a patient-specific a lab-on-chip cardiac microtissue model of dystrophin deficient cardiomyopathy. Host: POLIMI (IT)

  • View or Apply

    Similar Positions